"The firm (UNIS) still has plenty of tricks up its sleeve, though ? Unilife announced an agreement on Tuesday with a top five pharma company in a new product category for a drug trial. And over the course of the next year, plenty of other big pharma players will be looking to test their products as well, so Unilife will have ample opportunities to prove itself."
UNS Price at posting:
66.0¢ Sentiment: Buy Disclosure: Held
